List view / Grid view
Bio 2017 opens this week and Drug Target Review’s Niamh Marriott spoke with Richard Soll, Senior Vice President, Research Service Division, WuXi AppTec and Salvatore La Rosa, Vice President Research and Development, Children’s Tumor Foundation, to get their perspectives on one of the event’s most pressing trends. Both will be…
A review of Keap1/Nrf2 modulation of ROS homeostasis, and its pivotal role in the pathogenesis of cancer, Type 2 diabetes mellitus & neurological disorders.
Included in this Targets In-Depth Focus: Intracellular target validation in cellular systems; New drug targets identified to defend against chlamydia infections using CRISPR and stem cells; Novel solutions for tough targets with real bite...
Included in this Stem Cells In-Depth Focus: Translating discoveries into therapies; The key to successful manufacturing of patient-specific cell therapies; Interview with Alessandro Prigione and James Adjaye...
Included in this Screening In-Depth Focus: Phenotypic and target-based screening; Killing cancer cells using clinical drug resistance; Inflammatory biomarkers as a herbal anti-arthritic drug discovery tool...
Research into innovative small molecule therapeutics with disease modifying potential in Alzheimer’s disease (AD) has been conducted at Alzheon since 2013.
Mass spectrometry (MS) performed under native-like conditions (nMS) is a promising approach for studying protein-drug interactions, and has already informed treatments of some of the most intractable diseases including cancer, diabetes and Alzheimer’s.
Since the sequence of the human genome was published some 20 years ago, omics strategies have enabled the generation of detailed molecular signatures of cancers and their subtypes.
Included in this issue: Technology convergence improves testing; Screening; Stem Cells; Targets; Mass Spectrometry; and Therapeutics in Alzheimer's disease...
The global 3D bioprinting market is predicted to reach $1.8 billion in revenue by 2027. IDTechEx's Dr Nadia Tsao explains why...
We caught up with Dr Josephine Bunch to find out how NPL are using the Cancer Research Grand Challenge funding & novel imaging techniques to map cancer tumours...
Draper's Joe Charest explains how synthetic organoids can lead to safer drug testing, and why organ-on-a-chip technology is the future of drug discovery...
GSK's top investigators explain why the data quality offered by Fluorescence lifetime detection technology for drug discovery applications is superior…
Mundipharma EDO GmbH's Dr Thomas Mehrling talks through the benefits of streamlining the drug discovery and development process using the EDO model...
We caught up with Andreas Laustsen Co-Founder and CEO of Venomab, to find the latest in antivenom research…
